JP2008540554A5 - - Google Patents

Download PDF

Info

Publication number
JP2008540554A5
JP2008540554A5 JP2008511312A JP2008511312A JP2008540554A5 JP 2008540554 A5 JP2008540554 A5 JP 2008540554A5 JP 2008511312 A JP2008511312 A JP 2008511312A JP 2008511312 A JP2008511312 A JP 2008511312A JP 2008540554 A5 JP2008540554 A5 JP 2008540554A5
Authority
JP
Japan
Prior art keywords
halo
group
hydrogen atom
alkyl
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008511312A
Other languages
English (en)
Other versions
JP5089578B2 (ja
JP2008540554A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/018061 external-priority patent/WO2006124447A2/en
Publication of JP2008540554A publication Critical patent/JP2008540554A/ja
Publication of JP2008540554A5 publication Critical patent/JP2008540554A5/ja
Application granted granted Critical
Publication of JP5089578B2 publication Critical patent/JP5089578B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (5)

  1. 次式で表される化合物、又はその薬理学的に許容できる塩。
    Figure 2008540554
    (I)
    (式中、
    はCN、NO、SOMe、C(O)Me、CH=NOMe又はヘテロ環を表し、
    はハロ、ハロ(C−C)アルキル又は(C−C)アルキル基を表し、
    は水素原子又は(C−C)アルキル基を表し、
    はアリール、ヘテロ環又はベンゼン融合ヘテロ環を表し、各々任意に以下からなる群から選択される1から2つの置換基:
    (a) ハロ、
    (b) (C−C)アルキル、
    (c) (C−C)アルコキシ、
    (d) ハロ(C−C)アルキル、
    (e) ハロ(C−C)アルコキシ、
    (f) SR
    (g) SO
    (h) アミノ、
    (i) NH−(C−C)アルキルアミン、
    (j) N,N−(C−C)ジアルキルアミン、
    (k) NHCOR及び
    (l) NHSO10で置換されてもよく、
    4aは水素又はメチル基を表し、
    は水素原子、OH、CHOH、ハロ又は(C−C)アルキル基を表し、
    は水素原子、OH又は(C−C)アルキル基を表し、
    但しR及びRが各々OHを表すとき、それらは同じ炭素原子と結合せず、
    からR10は各々独立に(C−C)アルキル基を表す。)
  2. がクロロ又はトリフルオロメチル基を表し、
    が水素原子、メチル又はエチルを表し、
    が次式の群を表し、
    Figure 2008540554
    が水素原子又はメチルを表し、
    が水素原子又はメチルを表す請求項1記載の化合物。
  3. 以下からなる群から選択される、請求項1記載の化合物。
    Figure 2008540554
  4. 薬理学的に許容できる担体、希釈剤又は賦形剤との組み合わせで、請求項1から3のいずれか1項記載の化合物を有効成分として含んでなる医薬組成物。
  5. 筋肉質量又は強さの減少、虚弱、性腺機能不全、骨粗鬆症、オステオペニア、骨質量又は密度(独立に、又はアンドロゲン剥奪療法の結果として発生する)の減少、骨折、骨格筋減少症、加齢に関連する機能低下(ARFD)、性衝動の減少、男性又は女性の性的機能不全、勃起障害、うつ病、前立腺癌、減少した認識能力又は嗜眠の治療用の薬物の製造のための、請求項1から3のいずれか1項記載の化合物又はその薬理学的に許容できる塩の使用。
JP2008511312A 2005-05-13 2006-05-10 選択的なアンドロゲン受容体調節物質としての置換型n−アリールピロリジン Expired - Fee Related JP5089578B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68091105P 2005-05-13 2005-05-13
US60/680,911 2005-05-13
PCT/US2006/018061 WO2006124447A2 (en) 2005-05-13 2006-05-10 Substituted n-arylpyrrolidines as selective androgen receptor modulators

Publications (3)

Publication Number Publication Date
JP2008540554A JP2008540554A (ja) 2008-11-20
JP2008540554A5 true JP2008540554A5 (ja) 2009-06-25
JP5089578B2 JP5089578B2 (ja) 2012-12-05

Family

ID=37057376

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008511312A Expired - Fee Related JP5089578B2 (ja) 2005-05-13 2006-05-10 選択的なアンドロゲン受容体調節物質としての置換型n−アリールピロリジン

Country Status (17)

Country Link
US (1) US7807691B2 (ja)
EP (1) EP1891038B1 (ja)
JP (1) JP5089578B2 (ja)
CN (1) CN101175747B (ja)
AT (1) ATE412647T1 (ja)
AU (1) AU2006247738A1 (ja)
BR (1) BRPI0610183A2 (ja)
CA (1) CA2608419A1 (ja)
CY (1) CY1108690T1 (ja)
DE (1) DE602006003432D1 (ja)
DK (1) DK1891038T3 (ja)
ES (1) ES2314922T3 (ja)
MX (1) MX2007014053A (ja)
PL (1) PL1891038T3 (ja)
PT (1) PT1891038E (ja)
SI (1) SI1891038T1 (ja)
WO (1) WO2006124447A2 (ja)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2617256C (en) * 2005-08-01 2014-07-15 Takeda Pharmaceutical Company Limited Cyclic amine compound
CA2670976C (en) 2006-11-30 2015-01-27 Atsushi Hasuoka Cyclic amine compound
TW200831080A (en) 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
DK2176220T3 (da) 2007-08-07 2013-06-10 Takeda Pharmaceutical Pyrrolidin-2-on-derivater som androgenreceptormodulatorer.
PT2222636E (pt) 2007-12-21 2013-07-16 Ligand Pharm Inc Moduladores seletivos de recetores de andrógeno (sarms) e suas utilizações
MX2010009162A (es) 2008-02-22 2010-12-21 Radius Health Inc Moduladores selectivos del receptor de androgeno.
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
WO2009131196A1 (ja) * 2008-04-24 2009-10-29 武田薬品工業株式会社 置換ピロリジン誘導体およびその用途
WO2009133861A1 (ja) * 2008-04-28 2009-11-05 武田薬品工業株式会社 環状アミン化合物
CA2788907A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
EP3106159A1 (en) 2010-05-12 2016-12-21 Radius Health, Inc. Therapeutic regimens
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
CA2828219A1 (en) * 2011-02-25 2012-08-30 Irm Llc Pyrazolo [1,5-a] pyridines as trk inhibitors
AR088082A1 (es) * 2011-10-13 2014-05-07 Lilly Co Eli Moduladores selectivos del receptor androgeno
US20150291596A1 (en) * 2012-11-16 2015-10-15 Biocryst Pharmaceuticals, Inc. Antiviral azasugar-containing nucleosides
CA2943611A1 (en) 2014-03-28 2015-10-01 Duke University Method of treating cancer using selective estrogen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
RU2022108295A (ru) 2016-06-22 2022-04-06 Эллипсес Фарма Лтд Способы лечения ar+ рака молочной железы
KR102557321B1 (ko) 2017-01-05 2023-07-18 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
AU2018346597B2 (en) 2017-10-06 2023-07-13 Forma Therapeutics, Inc. Inhibiting Ubiquitin Specific Peptidase 30
EP3817821A1 (en) 2018-07-04 2021-05-12 Radius Pharmaceuticals, Inc. Polymorphic forms of rad 1901-2hcl
EP3860989B1 (en) 2018-10-05 2023-04-05 Forma Therapeutics, Inc. Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
CA3138197A1 (en) 2019-05-14 2020-11-19 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2021098810A1 (zh) * 2019-11-20 2021-05-27 南京明德新药研发有限公司 用作选择性雄激素受体调节剂的化合物
IL306010A (en) 2021-03-23 2023-11-01 Nuvation Bio Inc Anticancer compounds against the nuclear hormone receptor
IL308104A (en) 2021-05-03 2023-12-01 Nuvation Bio Inc Nuclear hormone receptor-targeted compounds against cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411981A (en) * 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2671348B1 (fr) * 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
US7649001B2 (en) * 2002-08-12 2010-01-19 Takeda Pharmaceutical Company Limited Fused benzene derivative and use
US7495016B2 (en) * 2002-10-21 2009-02-24 Irm Llc Pyrrolidones with anti-HIV activity
EP1654221A2 (en) 2003-06-10 2006-05-10 Smithkline Beecham Corporation Aniline derivatived androgen-, glucocorticoid-, mineralcorticoid- and progesterone- receptor modulators

Similar Documents

Publication Publication Date Title
JP2008540554A5 (ja)
JP2008546791A5 (ja)
HRP20210291T1 (hr) Imunoregulatorna sredstva
JP2009504763A5 (ja)
JP2017526677A5 (ja)
JP2015537020A5 (ja)
JP2006151984A5 (ja)
JP2009523760A5 (ja)
JP2006528597A5 (ja)
RU2502730C2 (ru) Сульфонамидные соединения и их применение
JP2005523922A5 (ja)
CY1110014T1 (el) Παραγωγα τετραϋδροκαρβαζολιου χρησιμα ως τροποποιητες υποδοχεα ανδρογονων (sarm)
DE602006003432D1 (de) Latoren des androgenrezeptors
JP2013056886A5 (ja)
JP2011527334A5 (ja)
SI1735278T1 (sl) Agenti histamin h receptorja priprava in terapevtska uporaba
JP2009504764A5 (ja)
JP2011504903A5 (ja)
JP2007508361A5 (ja)
EA200970500A1 (ru) СОЕДИНЕНИЯ ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА АНДРОГЕНОВ
JP2014505107A5 (ja)
JP2020505354A5 (ja)
JP2008544975A5 (ja)
CY1111744T1 (el) Τροποποιητες της δραστηριοτητας toy υποδοχεα χημειοκινων, κρυσταλλικες μορφες και διεργασια
JP2010539091A5 (ja)